SCHEMBL5999643

SCHEMBL5999643

Cc1ccc(N(C)c2ccncc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 1/20 0.54
CHKA P35790 1/20 0.54
ALDH1A1 P00352 1/20 0.50
TSHR P16473 1/20 0.50
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
ALOX15 P16050 1/20 0.42
CASP1 P29466 1/20 0.42
RAB9A P51151 1/20 0.42
HBB P68871 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4C Q9H3R0 1/20 0.41
DHFR P00374 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
ACHE P22303 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
GRM1 Q13255 1/20 0.37
CES1 P23141 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3409151 0.87 CHRM5 (0.68) CHRM5CHKAALDH1A1TSHRMAPT
SCHEMBL517128 0.84 ALDH1A1 (0.67) ALDH1A1TSHRMAPTSMN1; SMN2ALOX15
SCHEMBL22083898 0.84 ALDH1A1 (0.67) ALDH1A1TSHRMAPTSMN1; SMN2ALOX15
SCHEMBL15854781 0.84 ALDH1A1 (0.67) ALDH1A1TSHRMAPTSMN1; SMN2ALOX15
SCHEMBL812498 0.84 ALDH1A1 (0.67) ALDH1A1TSHRMAPTSMN1; SMN2ALOX15
SCHEMBL12593354 0.83 CHRM5 (0.50) CHRM5CHKAALDH1A1TSHRMAPT
SCHEMBL13367579 0.82 CHRM5 (0.50) CHRM5CHKAALDH1A1TSHRMAPT
SCHEMBL177904 0.79 MAPT (0.52) CHRM5CHKAALDH1A1TSHRMAPT
SCHEMBL20628911 0.79 CHRM5 (0.46) CHRM5CHKAALDH1A1TSHRMAPT
SCHEMBL2222390 0.79 CHKA (0.52) CHRM5CHKAALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11706938-B2 Photoelectric conversion element and photoelectric conversion module RICOH COMPANY, LTD. (JP) 2023-07-18 US disclosed
US-11706938-B2 Photoelectric conversion element and photoelectric conversion module RICOH COMPANY, LTD. (JP) 2023-07-18 US disclosed
US-20220392714-A1 PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION MODULE, ELECTRONIC DEVICE, AND POWER SUPPLY MODULE RICOH COMPANY, LTD. (JP) 2022-12-08 US disclosed
US-20210280809-A1 PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTRIC CONVERSION MODULE RICOH COMPANY, LTD. (JP) 2021-09-09 US disclosed
US-20210013412-A1 PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTRIC CONVERSION ELEMENT MODULE RICOH COMPANY, LTD. (JP) 2021-01-14 US disclosed
US-20200273630-A1 PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL TANAKA YUUJI (JP) 2020-08-27 US disclosed
US-10636579-B2 Photoelectric conversion element and solar cell RICOH COMPANY, LTD. (JP) 2020-04-28 US disclosed
US-20170069431-A1 PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL RICOH COMPANY, LTD. (JP) 2017-03-09 US disclosed
US-20170069431-A1 PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL RICOH COMPANY, LTD. (JP) 2017-03-09 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant SCHERING CORPORATION 2007-06-21 US disclosed
US-7220735-B2 Benzimidazolone histamine H3 antagonists SCHERING CORPORATION (US) 2007-05-22 US disclosed
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant CNR2, GPR119, GLP1R CHRM5 312/4885CHKA 469/4885ALDH1A1 3184/4885
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CHRM5 96/4885CHKA 407/4885ALDH1A1 1891/4885
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF CHRM5 4885/4885CHKA 288/4885ALDH1A1 2759/4885
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas BRAF, RAF1, ARAF CHRM5 4885/4885CHKA 288/4885ALDH1A1 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.